The European healthcare technology sector has entered a protracted period of structural realignment, precipitated by the breakdown of the historical venture capital funding escalator. Between 2020 and 2021, zero-interest-rate monetary policies and temporary pandemic tailwinds channeled speculative capital into early-stage digital health platforms, creating inflated entry valuations and subsidising unsustainable operational burn rates.

The European healthcare technology, medical devices (Medtech) and artificial intelligence (Health AI) ecosystems have transitioned from post-pandemic venture fragmentation into a disciplined era of industrial maturity. Following a severe liquidity drought that curtailed capital deployment and delayed public listings between late 2021 and 2024, the public offering window is reopening under fundamentally altered underwriting standards. Institutional public equity allocators no